Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
2(17%)
Results Posted
80%(4 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
1
8%
Ph not_applicable
5
42%
Ph phase_3
4
33%

Phase Distribution

1

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 3Large-scale testing
4(40.0%)
N/ANon-phased studies
5(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(3)
Completed(5)
Terminated(1)
Other(3)

Detailed Status

Completed5
unknown3
Recruiting2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 34 (40.0%)
N/A5 (50.0%)

Trials by Status

unknown325%
not_yet_recruiting18%
recruiting217%
terminated18%
completed542%

Recent Activity

2 active trials
Showing 5 of 12
recruiting

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

NCT04235764
completedphase_1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

NCT03258593
recruitingnot_applicable

Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm

NCT05779631
completednot_applicable

Effect of Tumor Base Size in Bladder Cancer

NCT06632340
terminatedphase_3

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT04688931
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04235764

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Recruiting
NCT03258593Phase 1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Completed
NCT05779631Not Applicable

Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm

Recruiting
NCT06632340Not Applicable

Effect of Tumor Base Size in Bladder Cancer

Completed
NCT04688931Phase 3

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Terminated
NCT06327932Phase 3

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

Not Yet Recruiting
NCT06046469Not Applicable

Validity of Computed Tomography Versus Magnetic Resonance Imaging in Predicting Muscular Invasion of Bladder Cancer

Unknown
NCT05467267

Personalized Urine Biomarker for Patients With Bladder Cancer

Unknown
NCT00461591Phase 3

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)

Completed
NCT04234165Not Applicable

Safety and Efficacy of Bipolar vs Monopolar Transurethral Resection of Bladder Tumor-A Randomized Controlled Trial

Completed
NCT00598806Phase 3

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

Completed
NCT02659332Not Applicable

Laser Treatment of Bladder Tumors in the Outpatient Department

Unknown

All 12 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
12